A-Alpha Bio
Seattle, WA
At A-Alpha Bio, we aim to accelerate target discovery, library screening, and preclinical drug characterization by providing cell-based tools for quantitative and high-throughput measurements of protein interactions. Current approaches for measuring protein interactions are insufficient for many drug development applications due to low accuracy or throughput. We are a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck. AlphaSeq is a revolutionary cell-based platform technology that will fundamentally change the way that protein interactions are measured. We are seeking industry partnerships to evaluate the use of AlphaSeq for a variety of drug development applications. A-Alpha Bio, Inc. was founded in 2017 as a spinout from the University of Washington's Institute for Protein Design and Center for Synthetic Biology.
aalphabio.comCompany Details
Founded
- 2017
Employees
- Between 20 - 100 employees
Raised
- $49,551,472
Headquarters Location
- Seattle, WA
Public
- No
Acquired
- No
CEO
- Frank Carpenito
Founders
- Randolph LopezDavid Younger
Company Collections
These are collections A-Alpha Bio is a part of. Click on the collection name to view similar companies.